Molecular Biosystems Inc. (NYSE:MB) of San Diego said thatsome of its shareholders have sued certain company officersand board members for knowingly misrepresenting thelikelihood and timing of final FDA approval of the company'scardiac ultrasound contrast agent, Albunex. MolecularBiosystems announced in mid-November that an FDA requestfor additional information on Albunex would likely delay itsapproval by at least several months.

(c) 1997 American Health Consultants. All rights reserved.